Propranolol is NOT appropriate for a 14-year-old with social anxiety disorder
The FDA label explicitly states that "safety and effectiveness of propranolol in pediatric patients have not been established," and the most recent clinical practice guidelines specifically exclude children and young patients under 18 years of age from treatment recommendations for social anxiety disorder 1.
Why This Recommendation is Clear
Guideline Evidence Against Use
The 2023 Japanese Society of Anxiety and Related Disorders/Japanese Society of Neuropsychopharmacology guidelines explicitly list "Children and young patients (under 18 years of age) with social anxiety disorder" as populations NOT covered by their treatment recommendations 2. These guidelines recommend SSRIs (fluvoxamine, paroxetine, escitalopram) and cognitive behavioral therapy (CBT) as first-line treatments—but only for adults over 18 years.
FDA Drug Label Concerns
The FDA labeling is unequivocal: propranolol's safety and effectiveness in pediatric patients remain unestablished 1. More concerning, bronchospasm and congestive heart failure have been reported coincident with propranolol administration in pediatric patients 1. This represents a significant safety signal that cannot be ignored.
Lack of Evidence for Efficacy
Recent systematic reviews and meta-analyses demonstrate no evidence supporting propranolol's effectiveness for social anxiety disorder even in adults 3, 4. The 2025 meta-analysis found no beneficial effect compared to placebo or benzodiazepines in social phobia patients (p ≥ 0.54) 3. The 2016 review concluded that "the quality of evidence for the efficacy of propranolol at present is insufficient to support the routine use of propranolol in the treatment of any of the anxiety disorders" 4.
What Should Be Done Instead
For a 14-year-old with social anxiety, prioritize:
- Cognitive Behavioral Therapy (CBT) as first-line treatment—this has established efficacy and safety in adolescents
- SSRIs (if pharmacotherapy is needed)—these have pediatric data and FDA approval for various anxiety disorders in children/adolescents
- Referral to child/adolescent psychiatry for comprehensive evaluation and evidence-based treatment planning
Important Clinical Caveats
- While propranolol is sometimes used off-label for performance anxiety or "stage fright" in adults 5, this is distinct from social anxiety disorder and lacks evidence even in that context
- The one pediatric study showing potential benefit was in autism spectrum disorder (ages 7-24), not social anxiety disorder, and even that trial showed no improvement in social interaction—only a marginal effect on anxiety 6
- Propranolol abuse has been documented in patients with social anxiety disorder who self-medicate, with doses up to 320 mg/day failing to control symptoms 7—highlighting both the drug's ineffectiveness and potential for misuse
The combination of lack of FDA approval, explicit guideline exclusion of pediatric patients, absence of efficacy data, and documented safety concerns makes propranolol inappropriate for this 14-year-old patient.